Cell Therapy Technologies Market - Global Forecast to 2029
商品番号 : SMB-19213
| 出版社 | MarketsandMarkets |
| 出版年月 | 2025年1月 |
| ページ数 | 466 |
| 図表数 | 571 |
| 価格タイプ | シングルユーザライセンス |
| 価格 | USD 4,950 |
| 種別 | 英文調査報告書 |
Report Overview
The global cell therapy technologies market is projected to surpass USD 6.80 billion in 2029 from USD 4.03 billion in 2024, with a significant CAGR of 11.0%.
世界の細胞治療技術市場は、2024年の40億3,000万米ドルから2029年には68億米ドルを超え、11.0%という大幅なCAGRで成長すると予測されています。
This market is driven by advancements in regenerative medicine, the rising prevalence of chronic diseases, increasing investments in research and development, and innovations in gene editing tools, such as CRISPR. Regulatory support and government funding, alongside strategic collaborations between biotech firms and academic institutions, are propelling the development of novel cell therapies, subsequently driving the market growth.
この市場は、再生医療の進歩、慢性疾患の有病率の上昇、研究開発への投資の増加、CRISPRなどの遺伝子編集ツールの革新によって牽引されています。規制上の支援と政府の資金提供は、バイオテクノロジー企業と学術機関との戦略的協力と並行して、新しい細胞療法の開発を推進し、その後の市場の成長を推進しています。
“The T cells cell therapy technologies segment accounted for the largest share in 2023.”
The cell therapy technologies market is bifurcated into three primary categories based on cell type, that are T cells, stem cells, and other cells. The T cells segment dominated the share of the market in the year 2023 due to being crucial in advancing immunotherapies, especially CAR-T therapies spurring substantial investments and technological innovations in T-cell engineering and scalable manufacturing. Advancements in CRISPR technology, ex vivo expansion, and “off-the-shelf” allogeneic solutions all further help in advancing market offerings.
“By application, the cancer application segment accounted for the largest share in the cell therapy technologies market.”
The application segment in the cell therapy technologies market includes cancer, cardiovascular disease (CVD), orthopaedic disorders, autoimmune diseases, and other applications. The cancer application dominated the segment due to increasing prevalence of cancer globally and the rising demand for innovative, targeted therapies. Advancements in cell engineering, scalable manufacturing, and emerging applications in solid tumors further enhance the growth potential of this segment. It possesses a solid clinical pipeline, and the government initiatives are very supportive with regulatory approvals for the growth of the segment.
“North America: the largest share of the cell therapy technologies market”
By region, the market is segment into North America, Europe, Asia Pacific, Latin America, the Middle East and Africa. North America dominated the cell therapy technologies market in 2023 and likely continue to be dominant during the forecast period. North America dominates the cell therapy technologies market due to its robust healthcare infrastructure, significant investments in research and development, and the presence of key market players. The region benefits from strong regulatory support, with agencies like the FDA streamlining approvals for innovative therapies. High prevalence of chronic diseases, increasing demand for personalized medicine, and advanced manufacturing facilities further bolster regions dominance.
In-depth interviews have been conducted with chief executive officers (CEOs), Directors, and other executives from various key organizations operating in the cell therapy technologies market.
The primary interviews conducted for this report can be categorized as follows:
- By Respondent: Supply Side- 70% and Demand Side 30%
- By Designation: Managers – 45%, CXO & Directors – 30%, and Executives – 25%
- By Region: North America -40%, Europe -25%, Asia-Pacific -25%, Latin America -5% and Middle East & Africa- 5%
Danaher Corporation (US), Merck KGaA (Germany), Thermo Fisher Scientific Inc. (US), Lonza (Switzerland), Sartorius AG (Germany), Agilent Technologies Inc. (US), Avantor, Inc. (US), Bio-Techne (US), Fresenius SE & Co KGAA (Germany), BD (US), Corning Incorporated (US), Terumo Corporation (Japan), GenScript (US), MaxCyte (US) and STEMCELL Technologies (Canada) are some of the major players operating in the cell therapy technologies market.
Research Coverage:
This research report categorizes the cell therapy technologies market product (media, sera, and reagents; cell engineering products; cell culture vessels; cell therapy equipment; systems & software; and other products), process (cell processing, cell preservation, cell distribution, cell handling, and process monitoring & quality control), cell type (T cells, stem cells, and other cells), application (cancer, cardiovascular disease (CVD), orthopedic disorders, autoimmune diseases, and other applications) end user (biopharmaceutical & biotechnology companies, CROs & CMOs, research institutes, and cell banks) and region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the cell therapy technologiess market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products, key strategies, collaborations, partnerships, and agreements. New launches, collaborations and acquisitions, and recent developments associated with the cell therapy technologies market.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the cell therapy technologies and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
- Analysis of key drivers (increased funding and investment in cell therapy, advancements in gene editing technologies, the development of automated cell processing systems, and regulatory support for fast-tracking therapies), restraints (manufacturing and logistical complexity), opportunities (personalized and off-the-shelf cell therapies, integration with digital technologies such as AI & ML) and Challenges (supply chain & cold chain management and manufacturing scalability & quality control).
- Product Development/Innovation: Detailed insights on maintaining a comprehensive and innovative product portfolio offering for cell therapy technologies.
- Market Development: Comprehensive information about lucrative markets – the report analyses the market across varied regions.
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the cell therapy technologies market.
- Competitive Assessment: Danaher Corporation (US), Merck KGaA (Germany), Thermo Fisher Scientific Inc. (US), Lonza (Switzerland), Sartorius AG (Germany), and among others in the market.
Table of Contents
1 INTRODUCTION 38
1.1 STUDY OBJECTIVES 38
1.2 MARKET DEFINITION 38
1.3 STUDY SCOPE 39
1.3.1 MARKET SEGMENTATION AND REGIONAL SCOPE 39
1.3.2 INCLUSIONS & EXCLUSIONS 40
1.3.3 YEARS CONSIDERED 40
1.3.4 CURRENCY CONSIDERED 40
1.4 STAKEHOLDERS 41
1.5 SUMMARY OF CHANGES 41
2 RESEARCH METHODOLOGY 43
2.1 RESEARCH DATA 43
2.1.1 SECONDARY DATA 44
2.1.2 PRIMARY DATA 45
2.2 MARKET ESTIMATION METHODOLOGY 46
2.2.1 MARKET ESTIMATION 46
2.2.2 INSIGHTS FROM PRIMARY EXPERTS 49
2.2.3 SEGMENTAL MARKET ESTIMATION (TOP-DOWN APPROACH) 49
2.3 MARKET GROWTH RATE PROJECTIONS 50
2.4 DATA TRIANGULATION 53
2.5 RESEARCH ASSUMPTIONS 54
2.6 RESEARCH LIMITATIONS 55
2.7 RISK ANALYSIS 55
3 EXECUTIVE SUMMARY 56
4 PREMIUM INSIGHTS 61
4.1 CELL THERAPY TECHNOLOGIES MARKET OVERVIEW 61
4.2 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET,
BY PRODUCT AND COUNTRY (2023) 62
4.3 CELL THERAPY TECHNOLOGIES MARKET SHARE, BY PRODUCT, 2024 VS. 2029 63
4.4 CELL THERAPY TECHNOLOGIES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 63
5 MARKET OVERVIEW 64
5.1 INTRODUCTION 64
5.2 MARKET DYNAMICS 64
5.2.1 DRIVERS 65
5.2.1.1 Increased funding and investment in cell therapy 65
5.2.1.2 Advancements in gene editing technologies 65
5.2.1.3 Development of automated cell processing systems 66
5.2.1.4 Regulatory support for fast-tracking therapies 66
5.2.2 RESTRAINTS 67
5.2.2.1 Manufacturing and logistical complexity 67
5.2.3 OPPORTUNITIES 68
5.2.3.1 Personalized and off-the-shelf cell therapies 68
5.2.3.2 Integration with digital technologies such as AI & ML 68
5.2.4 CHALLENGES 69
5.2.4.1 Supply chain & cold chain management and manufacturing scalability & quality control 69
5.3 ECOSYSTEM ANALYSIS 69
5.3.1 PRODUCT PROVIDERS 70
5.3.2 END USERS 71
5.3.3 REGULATORY BODIES 71
5.4 TECHNOLOGY ANALYSIS 72
5.4.1 KEY TECHNOLOGIES 72
5.4.1.1 Magnetic-activated cell sorting 72
5.4.1.2 Cryopreservation 73
5.4.1.3 Gene editing technologies 73
5.4.1.4 Bioprocessing technologies 73
5.4.2 COMPLEMENTARY TECHNOLOGIES 73
5.4.2.1 Artificial intelligence and machine learning 73
5.4.2.2 Biomaterials and scaffolding 74
5.4.2.3 Automation and scalability 74
5.4.3 ADJACENT TECHNOLOGIES 74
5.4.3.1 Nanotechnology 74
5.4.3.2 Immunotherapy platforms 74
5.5 PRICING ANALYSIS 75
5.5.1 AVERAGE SELLING PRICE TREND OF CELL THERAPY PRODUCTS,
BY KEY PLAYER, 2022–2024 75
5.5.2 AVERAGE SELLING PRICE TREND OF CELL THERAPY EQUIPMENT,
BY REGION, 2022–2024 76
5.6 VALUE CHAIN ANALYSIS 78
5.7 PATENT ANALYSIS 79
5.8 TRADE ANALYSIS 81
5.8.1 IMPORT DATA FOR MACHINES AND APPARATUS FOR ELECTROPLATING, ELECTROLYSIS, OR ELECTROPHORESIS (HS CODE: 854330) 81
5.8.2 EXPORT DATA FOR MACHINES AND APPARATUS FOR ELECTROPLATING, ELECTROLYSIS, OR ELECTROPHORESIS (HS CODE: 854330) 82
5.9 KEY CONFERENCES AND EVENTS, 2025–2026 83
5.10 REGULATORY LANDSCAPE 84
5.10.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 85
5.10.2 REGULATORY FRAMEWORK 87
5.10.2.1 North America 87
5.10.2.2 Europe 88
5.10.2.3 Asia Pacific 88
5.10.2.4 Rest of the World 88
5.11 PORTER’S FIVE FORCES ANALYSIS 89
5.11.1 THREAT OF NEW ENTRANTS 90
5.11.2 THREAT OF SUBSTITUTES 90
5.11.3 BARGAINING POWER OF BUYERS 90
5.11.4 BARGAINING POWER OF SUPPLIERS 90
5.11.5 INTENSITY OF COMPETITIVE RIVALRY 90
5.12 KEY STAKEHOLDERS AND BUYING CRITERIA 91
5.12.1 KEY STAKEHOLDERS 91
5.12.2 BUYING CRITERIA 92
5.13 INVESTMENT & FUNDING SCENARIO 94
5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESSES 95
5.15 IMPACT OF AI/GEN AI ON CELL THERAPY TECHNOLOGIES MARKET 96
6 CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT 98
6.1 INTRODUCTION 99
6.2 MEDIA, SERA, AND REAGENTS 99
6.2.1 IMPORTANCE OF MEDIA, SERA, AND REAGENTS IN CELL PROCESSING
TO DRIVE MARKET 99
6.3 CELL THERAPY EQUIPMENT 103
6.3.1 CELL PROCESSING EQUIPMENT 106
6.3.1.1 Development of automated and closed-system cell processing equipment to accelerate segment growth 106
6.3.2 SINGLE-USE EQUIPMENT 110
6.3.2.1 Increasing funding for stem cell therapy to drive market 110
6.3.3 OTHER CELL THERAPY EQUIPMENT 113
6.4 SYSTEMS & SOFTWARE 116
6.4.1 RISING DEMAND FOR CELL THERAPIES TO SUPPORT MARKET GROWTH 116
6.5 CELL CULTURE VESSELS 120
6.5.1 RISING R&D AND INVESTMENTS IN CELL-BASED THERAPIES TO
DRIVE DEMAND 120
6.6 CELL ENGINEERING PRODUCTS 123
6.6.1 AVAILABILITY OF WIDE RANGE OF CELL ENGINEERING PRODUCTS TO SUPPORT MARKET 123
6.7 OTHER PRODUCTS 127
7 CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS 130
7.1 INTRODUCTION 131
7.2 CELL PROCESSING 131
7.2.1 CELL EXPANSION 135
7.2.1.1 Rising demand for personalized and regenerative therapies to
drive market growth 135
7.2.2 CELL ISOLATION 138
7.2.2.1 Rising need for scalable, efficient isolation technologies to
drive market 138
7.2.3 CELL CHARACTERIZATION 142
7.2.3.1 Increasing demand for high-quality, safe, and effective
cell-based therapies to propel growth 142
7.2.4 CELL COLLECTION 145
7.2.4.1 Advancements in cell collection technologies to drive market 145
7.3 CELL PRESERVATION 149
7.3.1 ADVANCEMENT IN CRYOPRESERVATION TECHNOLOGIES TO DRIVE GROWTH 149
7.4 PROCESS MONITORING & QUALITY CONTROL 152
7.4.1 INCREASING DEMAND FOR AUTOMATED QUALITY CONTROL IN
CELL THERAPY PRODUCTION TO DRIVE MARKET 152
7.5 CELL HANDLING 156
7.5.1 INCREASING DEMAND FOR AUTOMATED, EFFICIENT,
AND SCALABLE SOLUTIONS TO DRIVE MARKET GROWTH 156
7.6 CELL DISTRIBUTION 159
7.6.1 INCREASED FOCUS ON TRANSPORTATION AND STORAGE TO
DRIVE MARKET GROWTH 159
8 CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE 163
8.1 INTRODUCTION 164
8.2 T CELLS 164
8.2.1 RISING RESEARCH ON CAR T-CELL THERAPY TO ACCELERATE GROWTH 164
8.3 STEM CELLS 168
8.3.1 INCREASING FUNDING FOR STEM CELL RESEARCH TO PROPEL MARKET 168
8.4 OTHER CELLS 172
9 CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION 176
9.1 INTRODUCTION 177
9.2 CANCER 177
9.2.1 RISING RESEARCH ON CAR T-CELL THERAPY TO ACCELERATE
SEGMENT GROWTH 177
9.3 CARDIOVASCULAR DISEASE 181
9.3.1 INCREASING FOCUS ON INNOVATIVE CELL THERAPY APPROACHES TO
DRIVE MARKET 181
9.4 ORTHOPEDIC DISORDERS 185
9.4.1 INCREASING FOCUS ON STEM CELL THERAPY FOR TISSUE REGENERATION
TO DRIVE MARKET 185
9.5 AUTOIMMUNE DISEASES 189
9.5.1 INCREASING FUNDING FOR STEM CELL RESEARCH TO
SUPPORT MARKET GROWTH 189
9.6 OTHER APPLICATIONS 192
10 CELL THERAPY TECHNOLOGIES MARKET, BY END USER 196
10.1 INTRODUCTION 197
10.2 BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 197
10.2.1 INCREASING ADOPTION OF INORGANIC GROWTH STRATEGIES
BY BIOPHARMACEUTICAL COMPANIES TO DRIVE MARKET 197
10.3 CROS & CMOS 201
10.3.1 FOCUS ON OUTSOURCING TO DRIVE SEGMENT GROWTH 201
10.4 RESEARCH INSTITUTES 205
10.4.1 RISING RESEARCH ACTIVITY TO SUPPORT MARKET GROWTH 205
10.5 CELL BANKS 209
10.5.1 INCREASING DEMAND FOR STANDARDIZED CELL LINES TO
SUPPORT MARKET GROWTH 209
11 CELL THERAPY TECHNOLOGIES MARKET, BY REGION 213
11.1 INTRODUCTION 214
11.2 NORTH AMERICA 214
11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 215
11.2.2 US 220
11.2.2.1 US dominates North American cell therapy technologies market 220
11.2.3 CANADA 223
11.2.3.1 Increasing government funding to drive adoption of
cell therapy instruments 223
11.3 EUROPE 227
11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 228
11.3.2 GERMANY 232
11.3.2.1 Germany to hold largest market share 232
11.3.3 UK 235
11.3.3.1 Favorable funding & investment scenario to drive market growth 235
11.3.4 FRANCE 239
11.3.4.1 Availability of government & private funding to
support market growth 239
11.3.5 ITALY 243
11.3.5.1 Increasing R&D, public & private investment, and support to offer growth opportunities 243
11.3.6 SPAIN 246
11.3.6.1 Advancement in personalized medicine to stimulate market 246
11.3.7 REST OF EUROPE 249
11.4 ASIA PACIFIC 253
11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 254
11.4.2 CHINA 259
11.4.2.1 Increasing R&D expenditure to drive market growth 259
11.4.3 JAPAN 263
11.4.3.1 Strong availability of funding to support market growth 263
11.4.4 INDIA 267
11.4.4.1 Rising funding programs to drive market 267
11.4.5 AUSTRALIA 271
11.4.5.1 Increasing government funding & initiatives to drive market growth 271
11.4.6 SOUTH KOREA 275
11.4.6.1 Alliances & investments in research to drive market 275
11.4.7 REST OF ASIA PACIFIC 278
11.5 LATIN AMERICA 282
11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 283
11.5.2 BRAZIL 287
11.5.2.1 Brazil to dominate Latin American market till 2029 287
11.5.3 MEXICO 291
11.5.3.1 Strong pharmaceutical industry and increased government support to augment market 291
11.5.4 REST OF LATIN AMERICA 295
11.6 MIDDLE EAST 299
11.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST 299
11.6.2 GCC COUNTRIES 304
11.6.2.1 Saudi Arabia 308
11.6.2.1.1 Increasing government investments in healthcare and growing pharmaceuticals industry to support market 308
11.6.2.2 UAE 312
11.6.2.2.1 Growing R&D expenditure & well-established class infrastructure to drive market 312
11.6.2.3 Rest of GCC Countries 315
11.6.3 REST OF MIDDLE EAST 319
11.7 AFRICA 323
11.7.1 MACROECONOMIC OUTLOOK FOR AFRICA 324
12 COMPETITIVE LANDSCAPE 329
12.1 OVERVIEW 329
12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 329
12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN CELL THERAPY TECHNOLOGIES MARKET 330
12.3 REVENUE ANALYSIS 331
12.4 MARKET SHARE ANALYSIS 331
12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 333
12.5.1 STARS 334
12.5.2 EMERGING LEADERS 334
12.5.3 PERVASIVE PLAYERS 334
12.5.4 PARTICIPANTS 334
12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023 336
12.5.5.1 Company footprint 336
12.5.5.2 Region footprint 337
12.5.5.3 Product footprint 338
12.5.5.4 Process footprint 339
12.5.5.5 Cell type footprint 340
12.5.5.6 Application footprint 341
12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 342
12.6.1 PROGRESSIVE COMPANIES 342
12.6.2 RESPONSIVE COMPANIES 342
12.6.3 DYNAMIC COMPANIES 342
12.6.4 STARTING BLOCKS 342
12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023 344
12.7 COMPANY VALUATION & FINANCIAL METRICS 345
12.7.1 FINANCIAL METRICS 345
12.7.2 COMPANY VALUATION 346
12.8 BRAND/PRODUCT COMPARISON 346
12.9 COMPETITIVE SCENARIO 347
12.9.1 PRODUCT LAUNCHES 347
12.9.2 DEALS 348
12.9.3 EXPANSIONS 349
13 COMPANY PROFILES 350
13.1 KEY PLAYERS 350
13.1.1 DANAHER CORPORATION 350
13.1.1.1 Business overview 350
13.1.1.2 Products offered 351
13.1.1.3 Recent developments 357
13.1.1.3.1 Product launches 357
13.1.1.3.2 Deals 357
13.1.1.3.3 Expansions 358
13.1.1.4 MnM view 358
13.1.1.4.1 Key strengths 358
13.1.1.4.2 Strategic choices 358
13.1.1.4.3 Weaknesses and competitive threats 358
13.1.2 MERCK KGAA 359
13.1.2.1 Business overview 359
13.1.2.2 Products offered 361
13.1.2.3 Recent developments 363
13.1.2.3.1 Deals 363
13.1.2.3.2 Expansions 363
13.1.2.4 MnM view 363
13.1.2.4.1 Key strengths 363
13.1.2.4.2 Strategic choices 364
13.1.2.4.3 Weaknesses and competitive threats 364
13.1.3 THERMO FISHER SCIENTIFIC INC. 365
13.1.3.1 Business overview 365
13.1.3.2 Products offered 367
13.1.3.3 Recent developments 377
13.1.3.3.1 Product launches 377
13.1.3.3.2 Deals 378
13.1.3.3.3 Expansions 379
13.1.3.4 MnM view 379
13.1.3.4.1 Key strengths 379
13.1.3.4.2 Strategic choices 379
13.1.3.4.3 Weaknesses and competitive threats 379
13.1.4 LONZA 380
13.1.4.1 Business overview 380
13.1.4.2 Products offered 381
13.1.4.3 Recent developments 386
13.1.4.3.1 Product launches 386
13.1.4.3.2 Deals 386
13.1.5 SARTORIUS AG 387
13.1.5.1 Business overview 387
13.1.5.2 Products offered 388
13.1.5.3 Recent developments 392
13.1.5.3.1 Product launches 392
13.1.5.3.2 Deals 393
13.1.5.3.3 Expansions 393
13.1.6 AGILENT TECHNOLOGIES, INC. 394
13.1.6.1 Business overview 394
13.1.6.2 Products offered 395
13.1.6.3 Recent developments 397
13.1.6.3.1 Product launches 397
13.1.6.3.2 Deals 397
13.1.7 AVANTOR, INC. 398
13.1.7.1 Business overview 398
13.1.7.2 Products offered 399
13.1.7.3 Recent developments 404
13.1.7.3.1 Deals 404
13.1.8 FRESENIUS SE & CO. KGAA 405
13.1.8.1 Business overview 405
13.1.8.2 Products offered 407
13.1.8.3 Recent developments 407
13.1.8.3.1 Deals 407
13.1.9 BECTON, DICKINSON AND COMPANY 408
13.1.9.1 Business overview 408
13.1.9.2 Products offered 409
13.1.9.3 Recent developments 411
13.1.9.3.1 Product launches 411
13.1.10 CORNING INCORPORATED 412
13.1.10.1 Business overview 412
13.1.10.2 Products offered 413
13.1.11 TERUMO CORPORATION 417
13.1.11.1 Business overview 417
13.1.11.2 Products offered 418
13.1.11.3 Recent developments 419
13.1.11.3.1 Product launches 419
13.1.11.3.2 Deals 420
13.1.11.3.3 Expansions 420
13.1.12 BIO-TECHNE 421
13.1.12.1 Business overview 421
13.1.12.2 Products offered 422
13.1.12.3 Recent developments 428
13.1.12.3.1 Product launches 428
13.1.12.3.2 Deals 429
13.1.12.3.3 Other developments 429
13.1.13 GENSCRIPT 430
13.1.13.1 Business overview 430
13.1.13.2 Products offered 431
13.1.13.3 Recent developments 434
13.1.13.3.1 Deals 434
13.1.14 MAXCYTE 435
13.1.14.1 Business overview 435
13.1.14.2 Products offered 436
13.1.14.3 Recent developments 438
13.1.14.3.1 Deals 438
13.1.15 STEMCELL TECHNOLOGIES 440
13.1.15.1 Business overview 440
13.1.15.2 Products offered 440
13.1.15.3 Recent developments 446
13.1.15.3.1 Product launches 446
13.1.15.3.2 Deals 446
13.2 OTHER PLAYERS 447
13.2.1 OXFORD BIOMEDICA PLC 447
13.2.2 ROOSTERBIO, INC. 448
13.2.3 TRAKCEL 449
13.2.4 L7 INFORMATICS, INC. 450
13.2.5 MILTENYI BIOTEC 451
13.2.6 REPLIGEN CORPORATION 452
13.2.7 MAK SYSTEM 453
13.2.8 ORIGEN BIOMEDICAL, INC. 454
13.2.9 IXCELLS BIOTECHNOLOGIES 455
13.2.10 KÖRBER AG 457
14 APPENDIX 458
14.1 DISCUSSION GUIDE 458
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 462
14.3 CUSTOMIZATION OPTIONS 464
14.4 RELATED REPORTS 464
14.5 AUTHOR DETAILS 465
LIST OF TABLES
TABLE 1 IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS 52
TABLE 2 CELL THERAPY TECHNOLOGIES MARKET: RISK ANALYSIS 55
TABLE 3 CELL THERAPY TECHNOLOGIES MARKET: KEY PRODUCT PROVIDERS 70
TABLE 4 CELL THERAPY TECHNOLOGIES MARKET: KEY END USERS 71
TABLE 5 CELL THERAPY TECHNOLOGIES MARKET: REGULATORY BODIES 72
TABLE 6 AVERAGE SELLING PRICE TREND OF CELL THERAPY PRODUCTS,
BY KEY PLAYER, 2022–2024 75
TABLE 7 AVERAGE SELLING PRICE TREND OF CELL THERAPY EQUIPMENT,
BY REGION, 2022–2024 76
TABLE 8 KEY PATENTS IN CELL THERAPY TECHNOLOGIES MARKET, 2021–2024 80
TABLE 9 IMPORT VOLUME FOR HS CODE 854330, 2019–2023 (UNITS) 82
TABLE 10 EXPORT VOLUME FOR HS CODE 854330, 2019–2023 (UNITS) 83
TABLE 11 CELL THERAPY TECHNOLOGIES MARKET:
DETAILED LIST OF CONFERENCES & EVENTS 83
TABLE 12 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 85
TABLE 13 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 85
TABLE 14 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 86
TABLE 15 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 87
TABLE 16 CELL THERAPY TECHNOLOGIES MARKET: PORTER’S FIVE FORCES ANALYSIS 90
TABLE 17 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP FOUR END USERS 92
TABLE 18 KEY BUYING CRITERIA FOR CELL THERAPY TECHNOLOGIES PRODUCTS,
BY END USER 93
TABLE 19 CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 99
TABLE 20 CELL THERAPY MEDIA, SERA, AND REAGENTS MARKET, BY REGION,
2022–2029 (USD MILLION) 100
TABLE 21 NORTH AMERICA: CELL THERAPY MEDIA, SERA, AND REAGENTS MARKET,
BY COUNTRY, 2022–2029 (USD MILLION) 100
TABLE 22 EUROPE: CELL THERAPY MEDIA, SERA, AND REAGENTS MARKET,
BY COUNTRY, 2022–2029 (USD MILLION) 101
TABLE 23 ASIA PACIFIC: CELL THERAPY MEDIA, SERA, AND REAGENTS MARKET,
BY COUNTRY, 2022–2029 (USD MILLION) 101
TABLE 24 LATIN AMERICA: CELL THERAPY MEDIA, SERA, AND REAGENTS MARKET,
BY COUNTRY, 2022–2029 (USD MILLION) 102
TABLE 25 MIDDLE EAST: CELL THERAPY MEDIA, SERA, AND REAGENTS MARKET,
BY REGION, 2022–2029 (USD MILLION) 102
TABLE 26 GCC COUNTRIES: CELL THERAPY MEDIA, SERA, AND REAGENTS MARKET,
BY COUNTRY, 2022–2029 (USD MILLION) 102
TABLE 27 CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2022–2029 (USD MILLION) 103
TABLE 28 CELL THERAPY EQUIPMENT MARKET, BY REGION, 2022–2029 (USD MILLION) 104
TABLE 29 NORTH AMERICA: CELL THERAPY EQUIPMENT MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 104
TABLE 30 EUROPE: CELL THERAPY EQUIPMENT MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 104
TABLE 31 ASIA PACIFIC: CELL THERAPY EQUIPMENT MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 105
TABLE 32 LATIN AMERICA: CELL THERAPY EQUIPMENT MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 105
TABLE 33 MIDDLE EAST: CELL THERAPY EQUIPMENT MARKET, BY REGION,
2022–2029 (USD MILLION) 105
TABLE 34 GCC COUNTRIES: CELL THERAPY EQUIPMENT MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 106
TABLE 35 CELL PROCESSING EQUIPMENT MARKET, BY REGION, 2022–2029 (USD MILLION) 107
TABLE 36 NORTH AMERICA: CELL PROCESSING EQUIPMENT MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 107
TABLE 37 EUROPE: CELL PROCESSING EQUIPMENT MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 108
TABLE 38 ASIA PACIFIC: CELL PROCESSING EQUIPMENT MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 108
TABLE 39 LATIN AMERICA: CELL PROCESSING EQUIPMENT MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 109
TABLE 40 MIDDLE EAST: CELL PROCESSING EQUIPMENT MARKET, BY REGION,
2022–2029 (USD MILLION) 109
TABLE 41 GCC COUNTRIES: CELL PROCESSING EQUIPMENT MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 109
TABLE 42 SINGLE-USE EQUIPMENT MARKET, BY REGION, 2022–2029 (USD MILLION) 110
TABLE 43 NORTH AMERICA: SINGLE-USE EQUIPMENT MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 111
TABLE 44 EUROPE: SINGLE-USE EQUIPMENT MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 111
TABLE 45 ASIA PACIFIC: SINGLE-USE EQUIPMENT MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 112
TABLE 46 LATIN AMERICA: SINGLE-USE EQUIPMENT MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 112
TABLE 47 MIDDLE EAST: SINGLE-USE EQUIPMENT MARKET, BY REGION,
2022–2029 (USD MILLION) 112
TABLE 48 GCC COUNTRIES: SINGLE-USE EQUIPMENT MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 113
TABLE 49 OTHER CELL THERAPY EQUIPMENT MARKET, BY REGION,
2022–2029 (USD MILLION) 113
TABLE 50 NORTH AMERICA: OTHER CELL THERAPY EQUIPMENT MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 114
TABLE 51 EUROPE: OTHER CELL THERAPY EQUIPMENT MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 114
TABLE 52 ASIA PACIFIC: OTHER CELL THERAPY EQUIPMENT MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 115
TABLE 53 LATIN AMERICA: OTHER CELL THERAPY EQUIPMENT MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 115
TABLE 54 MIDDLE EAST: OTHER CELL THERAPY EQUIPMENT MARKET, BY REGION,
2022–2029 (USD MILLION) 115
TABLE 55 GCC COUNTRIES: OTHER CELL THERAPY EQUIPMENT MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 116
TABLE 56 CELL THERAPY SYSTEMS & SOFTWARE, BY COMPANY 116
TABLE 57 CELL THERAPY SYSTEMS & SOFTWARE MARKET, BY REGION,
2022–2029 (USD MILLION) 117
TABLE 58 NORTH AMERICA: CELL THERAPY SYSTEMS & SOFTWARE MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 117
TABLE 59 EUROPE: CELL THERAPY SYSTEMS & SOFTWARE MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 118
TABLE 60 ASIA PACIFIC: CELL THERAPY SYSTEMS & SOFTWARE MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 118
TABLE 61 LATIN AMERICA: CELL THERAPY SYSTEMS & SOFTWARE MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 119
TABLE 62 MIDDLE EAST: CELL THERAPY SYSTEMS & SOFTWARE MARKET, BY REGION, 2022–2029 (USD MILLION) 119
TABLE 63 GCC COUNTRIES: CELL THERAPY SYSTEMS & SOFTWARE MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 119
TABLE 64 CELL CULTURE VESSELS MARKET, BY REGION, 2022–2029 (USD MILLION) 120
TABLE 65 NORTH AMERICA: CELL CULTURE VESSELS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 121
TABLE 66 EUROPE: CELL CULTURE VESSELS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 121
TABLE 67 ASIA PACIFIC: CELL CULTURE VESSELS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 122
TABLE 68 LATIN AMERICA: CELL CULTURE VESSELS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 122
TABLE 69 MIDDLE EAST: CELL CULTURE VESSELS MARKET, BY REGION,
2022–2029 (USD MILLION) 122
TABLE 70 GCC COUNTRIES: CELL CULTURE VESSELS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 123
TABLE 71 CELL ENGINEERING PRODUCTS OFFERED, BY COMPANY 123
TABLE 72 CELL ENGINEERING PRODUCTS MARKET, BY REGION, 2022–2029 (USD MILLION) 124
TABLE 73 NORTH AMERICA: CELL ENGINEERING PRODUCTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 124
TABLE 74 EUROPE: CELL ENGINEERING PRODUCTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 125
TABLE 75 ASIA PACIFIC: CELL ENGINEERING PRODUCTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 125
TABLE 76 LATIN AMERICA: CELL ENGINEERING PRODUCTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 126
TABLE 77 MIDDLE EAST: CELL ENGINEERING PRODUCTS MARKET, BY REGION,
2022–2029 (USD MILLION) 126
TABLE 78 GCC COUNTRIES: CELL ENGINEERING PRODUCTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 126
TABLE 79 OTHER CELL THERAPY PRODUCTS MARKET, BY REGION,
2022–2029 (USD MILLION) 127
TABLE 80 NORTH AMERICA: OTHER CELL THERAPY PRODUCTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 127
TABLE 81 EUROPE: OTHER CELL THERAPY PRODUCTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 128
TABLE 82 ASIA PACIFIC: OTHER CELL THERAPY PRODUCTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 128
TABLE 83 LATIN AMERICA: OTHER CELL THERAPY PRODUCTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 129
TABLE 84 MIDDLE EAST: OTHER CELL THERAPY PRODUCTS MARKET, BY REGION,
2022–2029 (USD MILLION) 129
TABLE 85 GCC COUNTRIES: OTHER CELL THERAPY PRODUCTS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 129
TABLE 86 CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS,
2022–2029 (USD MILLION) 131
TABLE 87 CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE,
2022–2029 (USD MILLION) 132
TABLE 88 CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY REGION, 2022–2029 (USD MILLION) 132
TABLE 89 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR
CELL PROCESSING, BY COUNTRY, 2022–2029 (USD MILLION) 132
TABLE 90 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING,
BY COUNTRY, 2022–2029 (USD MILLION) 133
TABLE 91 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING,
BY COUNTRY, 2022–2029 (USD MILLION) 133
TABLE 92 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY COUNTRY, 2022–2029 (USD MILLION) 134
TABLE 93 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY REGION, 2022–2029 (USD MILLION) 134
TABLE 94 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY COUNTRY, 2022–2029 (USD MILLION) 134
TABLE 95 CELL THERAPY TECHNOLOGIES MARKET FOR CELL EXPANSION, BY REGION, 2022–2029 (USD MILLION) 135
TABLE 96 CELL THERAPY TECHNOLOGIES MARKET FOR CELL EXPANSION, BY COUNTRY, 2022–2029 (USD MILLION) 136
TABLE 97 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL EXPANSION,
BY COUNTRY, 2022–2029 (USD MILLION) 136
TABLE 98 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CELL EXPANSION,
BY COUNTRY, 2022–2029 (USD MILLION) 137
TABLE 99 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL EXPANSION, BY COUNTRY, 2022–2029 (USD MILLION) 137
TABLE 100 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR CELL EXPANSION,
BY REGION, 2022–2029 (USD MILLION) 137
TABLE 101 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR CELL EXPANSION, BY COUNTRY, 2022–2029 (USD MILLION) 138
TABLE 102 CELL THERAPY TECHNOLOGIES MARKET FOR CELL ISOLATION, BY REGION,
2022–2029 (USD MILLION) 139
TABLE 103 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL ISOLATION, BY COUNTRY, 2022–2029 (USD MILLION) 139
TABLE 104 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL ISOLATION,
BY COUNTRY, 2022–2029 (USD MILLION) 140
TABLE 105 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CELL ISOLATION,
BY COUNTRY, 2022–2029 (USD MILLION) 140
TABLE 106 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL ISOLATION,
BY COUNTRY, 2022–2029 (USD MILLION) 141
TABLE 107 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR CELL ISOLATION,
BY REGION, 2022–2029 (USD MILLION) 141
TABLE 108 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR CELL ISOLATION, BY COUNTRY, 2022–2029 (USD MILLION) 141
TABLE 109 CELL THERAPY TECHNOLOGIES MARKET FOR CELL CHARACTERIZATION, BY REGION, 2022–2029 (USD MILLION) 142
TABLE 110 CELL THERAPY TECHNOLOGIES MARKET FOR CELL CHARACTERIZATION,
BY COUNTRY, 2022–2029 (USD MILLION) 143
TABLE 111 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL CHARACTERIZATION, BY COUNTRY, 2022–2029 (USD MILLION) 143
TABLE 112 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CELL CHARACTERIZATION, BY COUNTRY, 2022–2029 (USD MILLION) 144
TABLE 113 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL CHARACTERIZATION, BY COUNTRY, 2022–2029 (USD MILLION) 144
TABLE 114 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR CELL CHARACTERIZATION, BY REGION, 2022–2029 (USD MILLION) 144
TABLE 115 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR CELL CHARACTERIZATION, BY COUNTRY, 2022–2029 (USD MILLION) 145
TABLE 116 CELL THERAPY TECHNOLOGIES MARKET FOR CELL COLLECTION, BY REGION, 2022–2029 (USD MILLION) 146
TABLE 117 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR
CELL COLLECTION, BY COUNTRY, 2022–2029 (USD MILLION) 146
TABLE 118 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL COLLECTION,
BY COUNTRY, 2022–2029 (USD MILLION) 147
TABLE 119 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CELL COLLECTION,
BY COUNTRY, 2022–2029 (USD MILLION) 147
TABLE 120 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL COLLECTION, BY COUNTRY, 2022–2029 (USD MILLION) 148
TABLE 121 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR CELL COLLECTION,
BY REGION, 2022–2029 (USD MILLION) 148
TABLE 122 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR CELL COLLECTION, BY COUNTRY, 2022–2029 (USD MILLION) 148
TABLE 123 CELL THERAPY TECHNOLOGIES MARKET FOR CELL PRESERVATION, BY REGION, 2022–2029 (USD MILLION) 149
TABLE 124 CELL THERAPY TECHNOLOGIES MARKET FOR CELL PRESERVATION, BY COUNTRY, 2022–2029 (USD MILLION) 150
TABLE 125 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PRESERVATION,
BY COUNTRY, 2022–2029 (USD MILLION) 150
TABLE 126 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PRESERVATION, BY COUNTRY, 2022–2029 (USD MILLION) 151
TABLE 127 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PRESERVATION, BY COUNTRY, 2022–2029 (USD MILLION) 151
TABLE 128 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR
CELL PRESERVATION, BY REGION, 2022–2029 (USD MILLION) 151
TABLE 129 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PRESERVATION, BY COUNTRY, 2022–2029 (USD MILLION) 152
TABLE 130 CELL THERAPY TECHNOLOGIES MARKET FOR PROCESS MONITORING &
QUALITY CONTROL, BY REGION, 2022–2029 (USD MILLION) 153
TABLE 131 CELL THERAPY TECHNOLOGIES MARKET FOR PROCESS MONITORING &
QUALITY CONTROL, BY COUNTRY, 2022–2029 (USD MILLION) 153
TABLE 132 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR PROCESS
MONITORING & QUALITY CONTROL, BY COUNTRY, 2022–2029 (USD MILLION) 154
TABLE 133 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR PROCESS MONITORING & QUALITY CONTROL, BY COUNTRY, 2022–2029 (USD MILLION) 154
TABLE 134 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR PROCESS MONITORING & QUALITY CONTROL, BY COUNTRY, 2022–2029 (USD MILLION) 155
TABLE 135 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR PROCESS MONITORING & QUALITY CONTROL, BY REGION, 2022–2029 (USD MILLION) 155
TABLE 136 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR PROCESS MONITORING & QUALITY CONTROL, BY COUNTRY, 2022–2029 (USD MILLION) 155
TABLE 137 CELL THERAPY TECHNOLOGIES MARKET FOR CELL HANDLING, BY REGION,
2022–2029 (USD MILLION) 156
TABLE 138 CELL THERAPY TECHNOLOGIES MARKET FOR CELL HANDLING, BY COUNTRY, 2022–2029 (USD MILLION) 157
TABLE 139 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL HANDLING,
BY COUNTRY, 2022–2029 (USD MILLION) 157
TABLE 140 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CELL HANDLING,
BY COUNTRY, 2022–2029 (USD MILLION) 158
TABLE 141 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL HANDLING,
BY COUNTRY, 2022–2029 (USD MILLION) 158
TABLE 142 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR CELL HANDLING,
BY REGION, 2022–2029 (USD MILLION) 158
TABLE 143 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR CELL HANDLING, BY COUNTRY, 2022–2029 (USD MILLION) 159
TABLE 144 CELL THERAPY TECHNOLOGIES MARKET FOR CELL DISTRIBUTION, BY REGION, 2022–2029 (USD MILLION) 160
TABLE 145 CELL THERAPY TECHNOLOGIES MARKET FOR CELL DISTRIBUTION, BY COUNTRY, 2022–2029 (USD MILLION) 160
TABLE 146 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR
CELL DISTRIBUTION, BY COUNTRY, 2022–2029 (USD MILLION) 161
TABLE 147 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR
CELL DISTRIBUTION, BY COUNTRY, 2022–2029 (USD MILLION) 161
TABLE 148 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR
CELL DISTRIBUTION, BY COUNTRY, 2022–2029 (USD MILLION) 162
TABLE 149 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR
CELL DISTRIBUTION, BY REGION, 2022–2029 (USD MILLION) 162
TABLE 150 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR
CELL DISTRIBUTION, BY COUNTRY, 2022–2029 (USD MILLION) 162
TABLE 151 CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE,
2022–2029 (USD MILLION) 164
TABLE 152 T-CELL THERAPY TECHNOLOGIES MARKET, BY REGION,
2022–2029 (USD MILLION) 165
TABLE 153 NORTH AMERICA: T-CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 165
TABLE 154 EUROPE: T-CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 166
TABLE 155 ASIA PACIFIC: T-CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 166
TABLE 156 LATIN AMERICA: T-CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 167
TABLE 157 MIDDLE EAST: T-CELL THERAPY TECHNOLOGIES MARKET, BY REGION,
2022–2029 (USD MILLION) 167
TABLE 158 GCC COUNTRIES: T-CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 167
TABLE 159 STEM CELL THERAPY TECHNOLOGIES MARKET, BY REGION,
2022–2029 (USD MILLION) 169
TABLE 160 NORTH AMERICA: STEM CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 169
TABLE 161 EUROPE: STEM CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 170
TABLE 162 ASIA PACIFIC: STEM CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 170
TABLE 163 LATIN AMERICA: STEM CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 171
TABLE 164 MIDDLE EAST: STEM CELL THERAPY TECHNOLOGIES MARKET, BY REGION,
2022–2029 (USD MILLION) 171
TABLE 165 GCC COUNTRIES: STEM CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 171
TABLE 166 OTHER CELL THERAPY TECHNOLOGIES MARKET, BY REGION,
2022–2029 (USD MILLION) 172
TABLE 167 NORTH AMERICA: OTHER CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 173
TABLE 168 EUROPE: OTHER CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 173
TABLE 169 ASIA PACIFIC: OTHER CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 174
TABLE 170 LATIN AMERICA: OTHER CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 174
TABLE 171 MIDDLE EAST: OTHER CELL THERAPY TECHNOLOGIES MARKET, BY REGION, 2022–2029 (USD MILLION) 174
TABLE 172 GCC COUNTRIES: OTHER CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 175
TABLE 173 CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 177
TABLE 174 CELL THERAPY TECHNOLOGIES MARKET FOR CANCER, BY REGION,
2022–2029 (USD MILLION) 178
TABLE 175 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CANCER,
BY COUNTRY, 2022–2029 (USD MILLION) 178
TABLE 176 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION) 179
TABLE 177 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION) 179
TABLE 178 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CANCER,
BY COUNTRY, 2022–2029 (USD MILLION) 180
TABLE 179 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR CANCER, BY REGION, 2022–2029 (USD MILLION) 180
TABLE 180 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR CANCER,
BY COUNTRY, 2022–2029 (USD MILLION) 180
TABLE 181 CELL THERAPY TECHNOLOGIES MARKET FOR CARDIOVASCULAR DISEASE,
BY REGION, 2022–2029 (USD MILLION) 182
TABLE 182 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR
CARDIOVASCULAR DISEASE, BY COUNTRY, 2022–2029 (USD MILLION) 182
TABLE 183 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR
CARDIOVASCULAR DISEASE, BY COUNTRY, 2022–2029 (USD MILLION) 183
TABLE 184 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR
CARDIOVASCULAR DISEASE, BY COUNTRY, 2022–2029 (USD MILLION) 183
TABLE 185 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR
CARDIOVASCULAR DISEASE, BY COUNTRY, 2022–2029 (USD MILLION) 184
TABLE 186 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR
CARDIOVASCULAR DISEASE, BY REGION, 2022–2029 (USD MILLION) 184
TABLE 187 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR
CARDIOVASCULAR DISEASE, BY COUNTRY, 2022–2029 (USD MILLION) 184
TABLE 188 CELL THERAPY TECHNOLOGIES MARKET FOR ORTHOPEDIC DISORDERS,
BY REGION, 2022–2029 (USD MILLION) 186
TABLE 189 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR
ORTHOPEDIC DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION) 186
TABLE 190 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR
ORTHOPEDIC DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION) 187
TABLE 191 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR
ORTHOPEDIC DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION) 187
TABLE 192 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR
ORTHOPEDIC DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION) 188
TABLE 193 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR
ORTHOPEDIC DISORDERS, BY REGION, 2022–2029 (USD MILLION) 188
TABLE 194 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR
ORTHOPEDIC DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION) 188
TABLE 195 CELL THERAPY TECHNOLOGIES MARKET FOR AUTOIMMUNE DISEASES,
BY REGION, 2022–2029 (USD MILLION) 189
TABLE 196 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR
AUTOIMMUNE DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 190
TABLE 197 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR
AUTOIMMUNE DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 190
TABLE 198 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR
AUTOIMMUNE DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 191
TABLE 199 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR
AUTOIMMUNE DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 191
TABLE 200 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR
AUTOIMMUNE DISEASES, BY REGION, 2022–2029 (USD MILLION) 191
TABLE 201 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR
AUTOIMMUNE DISEASES, BY COUNTRY, 2022–2029 (USD MILLION) 192
TABLE 202 CELL THERAPY TECHNOLOGIES MARKET FOR OTHER APPLICATIONS,
BY REGION, 2022–2029 (USD MILLION) 192
TABLE 203 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR
OTHER APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 193
TABLE 204 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR
OTHER APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 193
TABLE 205 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR
OTHER APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 194
TABLE 206 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR
OTHER APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 194
TABLE 207 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR
OTHER APPLICATIONS, BY REGION, 2022–2029 (USD MILLION) 194
TABLE 208 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR
OTHER APPLICATIONS, BY COUNTRY, 2022–2029 (USD MILLION) 195
TABLE 209 CELL THERAPY TECHNOLOGIES MARKET, BY END USER,
2022–2029 (USD MILLION) 197
TABLE 210 CELL THERAPY TECHNOLOGIES MARKET FOR BIOPHARMACEUTICAL
& BIOTECHNOLOGY COMPANIES, BY REGION, 2022–2029 (USD MILLION) 198
TABLE 211 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY,
2022–2029 (USD MILLION) 199
TABLE 212 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR BIOPHARMACEUTICAL
& BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION) 199
TABLE 213 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION) 200
TABLE 214 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY,
2022–2029 (USD MILLION) 200
TABLE 215 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2022–2029 (USD MILLION) 201
TABLE 216 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR BIOPHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY,
2022–2029 (USD MILLION) 201
TABLE 217 CELL THERAPY TECHNOLOGIES MARKET FOR CROS & CMOS, BY REGION,
2022–2029 (USD MILLION) 202
TABLE 218 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CROS & CMOS,
BY COUNTRY, 2022–2029 (USD MILLION) 203
TABLE 219 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CROS & CMOS,
BY COUNTRY, 2022–2029 (USD MILLION) 203
TABLE 220 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CROS & CMOS,
BY COUNTRY, 2022–2029 (USD MILLION) 204
TABLE 221 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CROS & CMOS,
BY COUNTRY, 2022–2029 (USD MILLION) 204
TABLE 222 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR CROS & CMOS,
BY REGION, 2022–2029 (USD MILLION) 204
TABLE 223 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR CROS & CMOS,
BY COUNTRY, 2022–2029 (USD MILLION) 205
TABLE 224 CELL THERAPY TECHNOLOGIES MARKET FOR RESEARCH INSTITUTES,
BY REGION, 2022–2029 (USD MILLION) 206
TABLE 225 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR
RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION) 206
TABLE 226 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR
RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION) 207
TABLE 227 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR
RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION) 207
TABLE 228 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR
RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION) 208
TABLE 229 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR
RESEARCH INSTITUTES, BY REGION, 2022–2029 (USD MILLION) 208
TABLE 230 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR
RESEARCH INSTITUTES, BY COUNTRY, 2022–2029 (USD MILLION) 208
TABLE 231 CELL THERAPY TECHNOLOGIES MARKET FOR CELL BANKS, BY REGION,
2022–2029 (USD MILLION) 209
TABLE 232 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL BANKS,
BY COUNTRY, 2022–2029 (USD MILLION) 210
TABLE 233 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL BANKS,
BY COUNTRY, 2022–2029 (USD MILLION) 210
TABLE 234 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CELL BANKS,
BY COUNTRY, 2022–2029 (USD MILLION) 211
TABLE 235 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL BANKS,
BY COUNTRY, 2022–2029 (USD MILLION) 211
TABLE 236 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR CELL BANKS,
BY REGION, 2022–2029 (USD MILLION) 211
TABLE 237 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR CELL BANKS,
BY COUNTRY, 2022–2029 (USD MILLION) 212
TABLE 238 CELL THERAPY TECHNOLOGIES MARKET, BY REGION, 2022–2029 (USD MILLION) 214
TABLE 239 NORTH AMERICA: KEY MACROINDICATORS 215
TABLE 240 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 216
TABLE 241 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 217
TABLE 242 NORTH AMERICA: CELL THERAPY EQUIPMENT MARKET, BY TYPE,
2022–2029 (USD MILLION) 217
TABLE 243 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS,
2022–2029 (USD MILLION) 218
TABLE 244 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR
CELL PROCESSING, BY TYPE, 2022–2029 (USD MILLION) 218
TABLE 245 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE,
2022–2029 (USD MILLION) 219
TABLE 246 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 219
TABLE 247 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER,
2022–2029 (USD MILLION) 220
TABLE 248 US: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 221
TABLE 249 US: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2022–2029 (USD MILLION) 221
TABLE 250 US: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS,
2022–2029 (USD MILLION) 222
TABLE 251 US: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2022–2029 (USD MILLION) 222
TABLE 252 US: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE,
2022–2029 (USD MILLION) 222
TABLE 253 US: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 223
TABLE 254 US: CELL THERAPY TECHNOLOGIES MARKET, BY END USER,
2022–2029 (USD MILLION) 223
TABLE 255 CANADA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 224
TABLE 256 CANADA: CELL THERAPY EQUIPMENT MARKET, BY TYPE,
2022–2029 (USD MILLION) 225
TABLE 257 CANADA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS,
2022–2029 (USD MILLION) 225
TABLE 258 CANADA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING,
BY TYPE, 2022–2029 (USD MILLION) 225
TABLE 259 CANADA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE,
2022–2029 (USD MILLION) 226
TABLE 260 CANADA: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 226
TABLE 261 CANADA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER,
2022–2029 (USD MILLION) 227
TABLE 262 EUROPE: KEY MACROINDICATORS 228
TABLE 263 EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 229
TABLE 264 EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 229
TABLE 265 EUROPE: CELL THERAPY EQUIPMENT MARKET, BY TYPE,
2022–2029 (USD MILLION) 230
TABLE 266 EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS,
2022–2029 (USD MILLION) 230
TABLE 267 EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING,
BY TYPE, 2022–2029 (USD MILLION) 230
TABLE 268 EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE,
2022–2029 (USD MILLION) 231
TABLE 269 EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 231
TABLE 270 EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY END USER,
2022–2029 (USD MILLION) 232
TABLE 271 GERMANY: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 233
TABLE 272 GERMANY: CELL THERAPY EQUIPMENT MARKET, BY TYPE,
2022–2029 (USD MILLION) 233
TABLE 273 GERMANY: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS,
2022–2029 (USD MILLION) 234
TABLE 274 GERMANY: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING,
BY TYPE, 2022–2029 (USD MILLION) 234
TABLE 275 GERMANY: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE,
2022–2029 (USD MILLION) 234
TABLE 276 GERMANY: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 235
TABLE 277 GERMANY: CELL THERAPY TECHNOLOGIES MARKET, BY END USER,
2022–2029 (USD MILLION) 235
TABLE 278 UK: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 236
TABLE 279 UK: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2022–2029 (USD MILLION) 237
TABLE 280 UK: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS,
2022–2029 (USD MILLION) 237
TABLE 281 UK: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2022–2029 (USD MILLION) 237
TABLE 282 UK: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE,
2022–2029 (USD MILLION) 238
TABLE 283 UK: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 238
TABLE 284 UK: CELL THERAPY TECHNOLOGIES MARKET, BY END USER,
2022–2029 (USD MILLION) 238
TABLE 285 FRANCE: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 240
TABLE 286 FRANCE: CELL THERAPY EQUIPMENT MARKET, BY TYPE,
2022–2029 (USD MILLION) 240
TABLE 287 FRANCE: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS,
2022–2029 (USD MILLION) 241
TABLE 288 FRANCE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING,
BY TYPE, 2022–2029 (USD MILLION) 241
TABLE 289 FRANCE: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE,
2022–2029 (USD MILLION) 242
TABLE 290 FRANCE: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 242
TABLE 291 FRANCE: CELL THERAPY TECHNOLOGIES MARKET, BY END USER,
2022–2029 (USD MILLION) 243
TABLE 292 ITALY: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 244
TABLE 293 ITALY: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2022–2029 (USD MILLION) 244
TABLE 294 ITALY: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS,
2022–2029 (USD MILLION) 245
TABLE 295 ITALY: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2022–2029 (USD MILLION) 245
TABLE 296 ITALY: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE,
2022–2029 (USD MILLION) 245
TABLE 297 ITALY: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 246
TABLE 298 ITALY: CELL THERAPY TECHNOLOGIES MARKET, BY END USER,
2022–2029 (USD MILLION) 246
TABLE 299 SPAIN: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 247
TABLE 300 SPAIN: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2022–2029 (USD MILLION) 247
TABLE 301 SPAIN: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS,
2022–2029 (USD MILLION) 248
TABLE 302 SPAIN: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING,
BY TYPE, 2022–2029 (USD MILLION) 248
TABLE 303 SPAIN: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE,
2022–2029 (USD MILLION) 248
TABLE 304 SPAIN: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 249
TABLE 305 SPAIN: CELL THERAPY TECHNOLOGIES MARKET, BY END USER,
2022–2029 (USD MILLION) 249
TABLE 306 REST OF EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 250
TABLE 307 REST OF EUROPE: CELL THERAPY EQUIPMENT MARKET, BY TYPE,
2022–2029 (USD MILLION) 251
TABLE 308 REST OF EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2022–2029 (USD MILLION) 251
TABLE 309 REST OF EUROPE: CELL THERAPY TECHNOLOGIES MARKET FOR
CELL PROCESSING, BY TYPE, 2022–2029 (USD MILLION) 252
TABLE 310 REST OF EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE,
2022–2029 (USD MILLION) 252
TABLE 311 REST OF EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 252
TABLE 312 REST OF EUROPE: CELL THERAPY TECHNOLOGIES MARKET, BY END USER,
2022–2029 (USD MILLION) 253
TABLE 313 ASIA PACIFIC: KEY MACROINDICATORS 254
TABLE 314 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 256
TABLE 315 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 256
TABLE 316 ASIA PACIFIC: CELL THERAPY EQUIPMENT MARKET, BY TYPE,
2022–2029 (USD MILLION) 257
TABLE 317 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS,
2022–2029 (USD MILLION) 257
TABLE 318 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING,
BY TYPE, 2022–2029 (USD MILLION) 257
TABLE 319 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE,
2022–2029 (USD MILLION) 258
TABLE 320 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 258
TABLE 321 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY END USER,
2022–2029 (USD MILLION) 259
TABLE 322 CHINA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 260
TABLE 323 CHINA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2022–2029 (USD MILLION) 260
TABLE 324 CHINA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS,
2022–2029 (USD MILLION) 261
TABLE 325 CHINA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2022–2029 (USD MILLION) 261
TABLE 326 CHINA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE,
2022–2029 (USD MILLION) 262
TABLE 327 CHINA: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 262
TABLE 328 CHINA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER,
2022–2029 (USD MILLION) 263
TABLE 329 JAPAN: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 264
TABLE 330 JAPAN: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2022–2029 (USD MILLION) 264
TABLE 331 JAPAN: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS,
2022–2029 (USD MILLION) 265
TABLE 332 JAPAN: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2022–2029 (USD MILLION) 265
TABLE 333 JAPAN: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE,
2022–2029 (USD MILLION) 266
TABLE 334 JAPAN: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 266
TABLE 335 JAPAN: CELL THERAPY TECHNOLOGIES MARKET, BY END USER,
2022–2029 (USD MILLION) 267
TABLE 336 INDIA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 268
TABLE 337 INDIA: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2022–2029 (USD MILLION) 268
TABLE 338 INDIA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS,
2022–2029 (USD MILLION) 269
TABLE 339 INDIA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2022–2029 (USD MILLION) 269
TABLE 340 INDIA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE,
2022–2029 (USD MILLION) 270
TABLE 341 INDIA: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 270
TABLE 342 INDIA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER,
2022–2029 (USD MILLION) 271
TABLE 343 AUSTRALIA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 272
TABLE 344 AUSTRALIA: CELL THERAPY EQUIPMENT MARKET, BY TYPE,
2022–2029 (USD MILLION) 272
TABLE 345 AUSTRALIA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS,
2022–2029 (USD MILLION) 273
TABLE 346 AUSTRALIA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING,
BY TYPE, 2022–2029 (USD MILLION) 273
TABLE 347 AUSTRALIA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE,
2022–2029 (USD MILLION) 274
TABLE 348 AUSTRALIA: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 274
TABLE 349 AUSTRALIA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER,
2022–2029 (USD MILLION) 275
TABLE 350 SOUTH KOREA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 276
TABLE 351 SOUTH KOREA: CELL THERAPY EQUIPMENT MARKET, BY TYPE,
2022–2029 (USD MILLION) 276
TABLE 352 SOUTH KOREA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS,
2022–2029 (USD MILLION) 277
TABLE 353 SOUTH KOREA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2022–2029 (USD MILLION) 277
TABLE 354 SOUTH KOREA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE,
2022–2029 (USD MILLION) 277
TABLE 355 SOUTH KOREA: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 278
TABLE 356 SOUTH KOREA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER,
2022–2029 (USD MILLION) 278
TABLE 357 REST OF ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 279
TABLE 358 REST OF ASIA PACIFIC: CELL THERAPY EQUIPMENT MARKET, BY TYPE,
2022–2029 (USD MILLION) 280
TABLE 359 REST OF ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2022–2029 (USD MILLION) 280
TABLE 360 REST OF ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET FOR
CELL PROCESSING, BY TYPE, 2022–2029 (USD MILLION) 281
TABLE 361 REST OF ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2022–2029 (USD MILLION) 281
TABLE 362 REST OF ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 281
TABLE 363 REST OF ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2022–2029 (USD MILLION) 282
TABLE 364 LATIN AMERICA: KEY MACROINDICATORS 283
TABLE 365 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY REGION,
2022–2029 (USD MILLION) 283
TABLE 366 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 284
TABLE 367 LATIN AMERICA: CELL THERAPY EQUIPMENT MARKET, BY TYPE,
2022–2029 (USD MILLION) 284
TABLE 368 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS,
2022–2029 (USD MILLION) 285
TABLE 369 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2022–2029 (USD MILLION) 285
TABLE 370 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE,
2022–2029 (USD MILLION) 286
TABLE 371 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 286
TABLE 372 LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER,
2022–2029 (USD MILLION) 287
TABLE 373 BRAZIL: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 288
TABLE 374 BRAZIL: CELL THERAPY EQUIPMENT MARKET, BY TYPE,
2022–2029 (USD MILLION) 288
TABLE 375 BRAZIL: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS,
2022–2029 (USD MILLION) 289
TABLE 376 BRAZIL: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2022–2029 (USD MILLION) 289
TABLE 377 BRAZIL: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE,
2022–2029 (USD MILLION) 290
TABLE 378 BRAZIL: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 290
TABLE 379 BRAZIL: CELL THERAPY TECHNOLOGIES MARKET, BY END USER,
2022–2029 (USD MILLION) 291
TABLE 380 MEXICO: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 292
TABLE 381 MEXICO: CELL THERAPY EQUIPMENT MARKET, BY TYPE,
2022–2029 (USD MILLION) 292
TABLE 382 MEXICO: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS,
2022–2029 (USD MILLION) 293
TABLE 383 MEXICO: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING,
BY TYPE, 2022–2029 (USD MILLION) 293
TABLE 384 MEXICO: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE,
2022–2029 (USD MILLION) 294
TABLE 385 MEXICO: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 294
TABLE 386 MEXICO: CELL THERAPY TECHNOLOGIES MARKET, BY END USER,
2022–2029 (USD MILLION) 295
TABLE 387 REST OF LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 296
TABLE 388 REST OF LATIN AMERICA: CELL THERAPY EQUIPMENT MARKET, BY TYPE,
2022–2029 (USD MILLION) 296
TABLE 389 REST OF LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2022–2029 (USD MILLION) 297
TABLE 390 REST OF LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET FOR
CELL PROCESSING, BY TYPE, 2022–2029 (USD MILLION) 297
TABLE 391 REST OF LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET,
BY CELL TYPE, 2022–2029 (USD MILLION) 298
TABLE 392 REST OF LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET,
BY APPLICATION, 2022–2029 (USD MILLION) 298
TABLE 393 REST OF LATIN AMERICA: CELL THERAPY TECHNOLOGIES MARKET,
BY END USER, 2022–2029 (USD MILLION) 299
TABLE 394 MIDDLE EAST: KEY MACROINDICATORS 300
TABLE 395 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET, BY REGION,
2022–2029 (USD MILLION) 300
TABLE 396 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 301
TABLE 397 MIDDLE EAST: CELL THERAPY EQUIPMENT MARKET, BY TYPE,
2022–2029 (USD MILLION) 301
TABLE 398 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS,
2022–2029 (USD MILLION) 302
TABLE 399 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2022–2029 (USD MILLION) 302
TABLE 400 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE,
2022–2029 (USD MILLION) 303
TABLE 401 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 303
TABLE 402 MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET, BY END USER,
2022–2029 (USD MILLION) 304
TABLE 403 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 304
TABLE 404 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 305
TABLE 405 GCC COUNTRIES: CELL THERAPY EQUIPMENT MARKET, BY TYPE,
2022–2029 (USD MILLION) 305
TABLE 406 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS,
2022–2029 (USD MILLION) 306
TABLE 407 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2022–2029 (USD MILLION) 306
TABLE 408 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE,
2022–2029 (USD MILLION) 307
TABLE 409 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 307
TABLE 410 GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET, BY END USER,
2022–2029 (USD MILLION) 308
TABLE 411 SAUDI ARABIA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 309
TABLE 412 SAUDI ARABIA: CELL THERAPY EQUIPMENT MARKET, BY TYPE,
2022–2029 (USD MILLION) 309
TABLE 413 SAUDI ARABIA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS,
2022–2029 (USD MILLION) 310
TABLE 414 SAUDI ARABIA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2022–2029 (USD MILLION) 310
TABLE 415 SAUDI ARABIA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE,
2022–2029 (USD MILLION) 311
TABLE 416 SAUDI ARABIA: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 311
TABLE 417 SAUDI ARABIA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER,
2022–2029 (USD MILLION) 312
TABLE 418 UAE: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 313
TABLE 419 UAE: CELL THERAPY EQUIPMENT MARKET, BY TYPE, 2022–2029 (USD MILLION) 313
TABLE 420 UAE: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS,
2022–2029 (USD MILLION) 314
TABLE 421 UAE: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2022–2029 (USD MILLION) 314
TABLE 422 UAE: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE,
2022–2029 (USD MILLION) 314
TABLE 423 UAE: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 315
TABLE 424 UAE: CELL THERAPY TECHNOLOGIES MARKET, BY END USER,
2022–2029 (USD MILLION) 315
TABLE 425 REST OF GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET,
BY PRODUCT, 2022–2029 (USD MILLION) 316
TABLE 426 REST OF GCC COUNTRIES: CELL THERAPY EQUIPMENT MARKET, BY TYPE,
2022–2029 (USD MILLION) 316
TABLE 427 REST OF GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET,
BY PROCESS, 2022–2029 (USD MILLION) 317
TABLE 428 REST OF GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET FOR
CELL PROCESSING, BY TYPE, 2022–2029 (USD MILLION) 317
TABLE 429 REST OF GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET,
BY CELL TYPE, 2022–2029 (USD MILLION) 318
TABLE 430 REST OF GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET,
BY APPLICATION, 2022–2029 (USD MILLION) 318
TABLE 431 REST OF GCC COUNTRIES: CELL THERAPY TECHNOLOGIES MARKET,
BY END USER, 2022–2029 (USD MILLION) 319
TABLE 432 REST OF MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT, 2022–2029 (USD MILLION) 320
TABLE 433 REST OF MIDDLE EAST: CELL THERAPY EQUIPMENT MARKET, BY TYPE,
2022–2029 (USD MILLION) 320
TABLE 434 REST OF MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS, 2022–2029 (USD MILLION) 321
TABLE 435 REST OF MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET FOR
CELL PROCESSING, BY TYPE, 2022–2029 (USD MILLION) 321
TABLE 436 REST OF MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE, 2022–2029 (USD MILLION) 322
TABLE 437 REST OF MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION, 2022–2029 (USD MILLION) 322
TABLE 438 REST OF MIDDLE EAST: CELL THERAPY TECHNOLOGIES MARKET, BY END USER, 2022–2029 (USD MILLION) 323
TABLE 439 AFRICA: KEY MACROINDICATORS 324
TABLE 440 AFRICA: CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT,
2022–2029 (USD MILLION) 325
TABLE 441 AFRICA: CELL THERAPY EQUIPMENT MARKET, BY TYPE,
2022–2029 (USD MILLION) 325
TABLE 442 AFRICA: CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS,
2022–2029 (USD MILLION) 326
TABLE 443 AFRICA: CELL THERAPY TECHNOLOGIES MARKET FOR CELL PROCESSING, BY TYPE, 2022–2029 (USD MILLION) 326
TABLE 444 AFRICA: CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE,
2022–2029 (USD MILLION) 327
TABLE 445 AFRICA: CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION,
2022–2029 (USD MILLION) 327
TABLE 446 AFRICA: CELL THERAPY TECHNOLOGIES MARKET, BY END USER,
2022–2029 (USD MILLION) 328
TABLE 447 OVERVIEW OF STRATEGIES DEPLOYED BY
KEY MANUFACTURING COMPANIES, 2021–2023 330
TABLE 448 CELL THERAPY TECHNOLOGIES MARKET: DEGREE OF COMPETITION 332
TABLE 449 CELL THERAPY TECHNOLOGIES MARKET: REGION FOOTPRINT 337
TABLE 450 CELL THERAPY TECHNOLOGIES MARKET: PRODUCT FOOTPRINT 338
TABLE 451 CELL THERAPY TECHNOLOGIES MARKET: PROCESS FOOTPRINT 339
TABLE 452 CELL THERAPY TECHNOLOGIES MARKET: CELL TYPE FOOTPRINT 340
TABLE 453 CELL THERAPY TECHNOLOGIES MARKET: APPLICATION FOOTPRINT 341
TABLE 454 CELL THERAPY TECHNOLOGIES MARKET: DETAILED LIST OF KEY STARTUPS/SMES 344
TABLE 455 CELL THERAPY TECHNOLOGIES MARKET:
COMPETITIVE BENCHMARKING OF STARTUPS/SMES 345
TABLE 456 CELL THERAPY TECHNOLOGIES MARKET:
PRODUCT LAUNCHES, JANUARY 2021–NOVEMBER 2024 347
TABLE 457 CELL THERAPY TECHNOLOGIES MARKET:
DEALS, JANUARY 2021– NOVEMBER 2024 348
TABLE 458 CELL THERAPY TECHNOLOGIES MARKET: EXPANSIONS, JANUARY 2021– NOVEMBER 2024 349
TABLE 459 DANAHER CORPORATION: COMPANY OVERVIEW 350
TABLE 460 DANAHER CORPORATION: PRODUCTS OFFERED 351
TABLE 461 DANAHER CORPORATION: PRODUCT LAUNCHES, JANUARY 2021– OCTOBER 2024 357
TABLE 462 DANAHER CORPORATION: DEALS, JANUARY 2021– OCTOBER 2024 357
TABLE 463 DANAHER CORPORATION: EXPANSIONS, JANUARY 2021– OCTOBER 2024 358
TABLE 464 MERCK KGAA: COMPANY OVERVIEW 359
TABLE 465 MERCK KGAA: PRODUCTS OFFERED 361
TABLE 466 MERCK KGAA: DEALS, JANUARY 2021–SEPTEMBER 2024 363
TABLE 467 MERCK KGAA: EXPANSIONS, JANUARY 2021–SEPTEMBER 2024 363
TABLE 468 THERMO FISHER SCIENTIFIC INC: COMPANY OVERVIEW 365
TABLE 469 THERMO FISHER SCIENTIFIC INC: PRODUCTS OFFERED 367
TABLE 470 THERMO FISHER SCIENTIFIC INC:
PRODUCT LAUNCHES, JANUARY 2021–SEPTEMBER 2024 377
TABLE 471 THERMO FISHER SCIENTIFIC INC: DEALS, JANUARY 2021–OCTOBER 2024 378
TABLE 472 THERMO FISHER SCIENTIFIC INC: EXPANSIONS, JANUARY 2021–OCTOBER 2024 379
TABLE 473 LONZA: COMPANY OVERVIEW 380
TABLE 474 LONZA: PRODUCTS OFFERED 381
TABLE 475 LONZA: PRODUCT LAUNCHES, JANUARY 2021– OCTOBER 2024 386
TABLE 476 LONZA: DEALS, JANUARY 2021– OCTOBER 2024 386
TABLE 477 SARTORIUS: COMPANY OVERVIEW 387
TABLE 478 SARTORIUS AG: PRODUCTS OFFERED 388
TABLE 479 SARTORIUS AG: PRODUCT LAUNCHES, JANUARY 2021–OCTOBER 2024 392
TABLE 480 SARTORIUS AG: DEALS, JANUARY 2021–OCTOBER 2024 393
TABLE 481 SARTORIUS AG: EXPANSIONS, JANUARY 2021– OCTOBER 2024 393
TABLE 482 AGILENT TECHNOLOGIES: COMPANY OVERVIEW 394
TABLE 483 AGILENT TECHNOLOGIES: PRODUCTS OFFERED 395
TABLE 484 AGILENT TECHNOLOGIES: PRODUCT LAUNCHES, JANUARY 2021–OCTOBER 2024 397
TABLE 485 AGILENT TECHNOLOGIES: DEALS, JANUARY 2021– OCTOBER 2024 397
TABLE 486 AVANTOR: COMPANY OVERVIEW 398
TABLE 487 AVANTOR: PRODUCTS OFFERED 399
TABLE 488 AVANTOR: DEALS, JANUARY 2021–OCTOBER 2024 404
TABLE 489 FRESENIUS: COMPANY OVERVIEW 405
TABLE 490 FRESENIUS: PRODUCTS OFFERED 407
TABLE 491 FRESENIUS: DEALS, JANUARY 2021–SEPTEMBER 2024 407
TABLE 492 BD: COMPANY OVERVIEW 408
TABLE 493 BD: PRODUCTS OFFERED 409
TABLE 494 BD: PRODUCT LAUNCHES, JANUARY 2021– OCTOBER 2024 411
TABLE 495 CORNING INCORPORATED: COMPANY OVERVIEW 412
TABLE 496 CORNING INCORPORATED: PRODUCTS OFFERED 413
TABLE 497 TERUMO CORPORATION: COMPANY OVERVIEW 417
TABLE 498 TERUMO CORPORATION: PRODUCTS OFFERED 418
TABLE 499 TERUMO CORPORATION: PRODUCT LAUNCHES, JANUARY 2021–OCTOBER 2024 419
TABLE 500 TERUMO CORPORATION: DEALS, JANUARY 2021–OCTOBER 2024 420
TABLE 501 TERUMO CORPORATION: EXPANSIONS, JANUARY 2021–OCTOBER 2024 420
TABLE 502 BIO-TECHNE: COMPANY OVERVIEW 421
TABLE 503 BIO-TECHNE: PRODUCTS OFFERED 422
TABLE 504 BIO-TECHNE: PRODUCT LAUNCHES, JANUARY 2021–OCTOBER 2024 428
TABLE 505 BIO-TECHNE: DEALS, JANUARY 2021–OCTOBER 2024 429
TABLE 506 BIO-TECHNE: OTHER DEVELOPMENTS, JANUARY 2021–OCTOBER 2024 429
TABLE 507 GENSCRIPT: COMPANY OVERVIEW 430
TABLE 508 GENSCRIPT: PRODUCTS OFFERED 431
TABLE 509 GENSCRIPT: DEALS, JANUARY 2021–OCTOBER 2024 434
TABLE 510 MAXCYTE: COMPANY OVERVIEW 435
TABLE 511 MAXCYTE: PRODUCTS OFFERED 436
TABLE 512 MAXCYTE: DEALS, JANUARY 2021–OCTOBER 2024 438
TABLE 513 STEMCELL TECHNOLOGIES: COMPANY OVERVIEW 440
TABLE 514 STEMCELL TECHNOLOGIES: PRODUCTS OFFERED 440
TABLE 515 STEMCELL TECHNOLOGIES: PRODUCT LAUNCHES,
JANUARY 2021– OCTOBER 2024 446
TABLE 516 STEMCELL TECHNOLOGIES: DEALS, JANUARY 2021–OCTOBER 2024 446
LIST OF FIGURES
FIGURE 1 CELL THERAPY TECHNOLOGIES MARKET SEGMENTATION AND REGIONAL SCOPE 39
FIGURE 2 CELL THERAPY TECHNOLOGIES MARKET: RESEARCH DESIGN 43
FIGURE 3 CELL THERAPY TECHNOLOGIES MARKET: BREAKDOWN OF PRIMARY INTERVIEWS 45
FIGURE 4 CELL THERAPY TECHNOLOGIES MARKET SIZE ESTIMATION
(SUPPLY-SIDE ANALYSIS), 2023 46
FIGURE 5 MARKET SIZE ESTIMATION APPROACH 1
(COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2023 47
FIGURE 6 ILLUSTRATIVE EXAMPLE OF DANAHER CORPORATION:
REVENUE SHARE ANALYSIS (2023) 47
FIGURE 7 MARKET SIZE VALIDATION FROM PRIMARY SOURCES 49
FIGURE 8 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 49
FIGURE 9 CELL THERAPY TECHNOLOGIES MARKET: CAGR PROJECTIONS 51
FIGURE 10 DATA TRIANGULATION METHODOLOGY 53
FIGURE 11 CELL THERAPY TECHNOLOGIES MARKET, BY PRODUCT,
2024 VS. 2029 (USD MILLION) 56
FIGURE 12 CELL THERAPY TECHNOLOGIES MARKET, BY PROCESS,
2024 VS. 2029 (USD MILLION) 57
FIGURE 13 CELL THERAPY TECHNOLOGIES MARKET, BY CELL TYPE,
2024 VS. 2029 (USD MILLION) 57
FIGURE 14 CELL THERAPY TECHNOLOGIES MARKET, BY APPLICATION,
2024 VS. 2029 (USD MILLION) 58
FIGURE 15 CELL THERAPY TECHNOLOGIES MARKET, BY END USER,
2024 VS. 2029 (USD MILLION) 59
FIGURE 16 GEOGRAPHICAL SNAPSHOT OF CELL THERAPY TECHNOLOGIES MARKET
(2024-2029) 60
FIGURE 17 INCREASED FUNDING & INVESTMENT IN CELL THERAPY AND
ADVANCEMENTS IN GENE EDITING TECHNOLOGIES TO DRIVE MARKET 61
FIGURE 18 US ACCOUNTED FOR LARGEST MARKET SHARE IN 2023 62
FIGURE 19 MEDIA, SERA, AND REAGENTS TO DOMINATE MARKET DURING FORECAST PERIOD 63
FIGURE 20 APAC COUNTRIES TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD 63
FIGURE 21 CELL THERAPY TECHNOLOGIES MARKET:
DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 64
FIGURE 22 CELL THERAPY TECHNOLOGIES MARKET: ECOSYSTEM 70
FIGURE 23 AVERAGE SELLING PRICE TREND OF CELL THERAPY EQUIPMENT,
2024 (USD THOUSAND) 77
FIGURE 24 CELL THERAPY TECHNOLOGIES MARKET: VALUE CHAIN ANALYSIS 78
FIGURE 25 CELL THERAPY TECHNOLOGIES MARKET: OVERVIEW OF PATENTING ACTIVITY 80
FIGURE 26 CELL THERAPY TECHNOLOGIES MARKET: PORTER’S FIVE FORCES ANALYSIS 89
FIGURE 27 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS 91
FIGURE 28 KEY BUYING CRITERIA FOR TOP FOUR END USERS 92
FIGURE 29 GOVERNMENT FUNDING FOR R&D FROM 2019–2024 95
FIGURE 30 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 96
FIGURE 31 CELL THERAPY TECHNOLOGIES MARKET: IMPACT OF AI 97
FIGURE 32 NORTH AMERICA: CELL THERAPY TECHNOLOGIES MARKET SNAPSHOT 216
FIGURE 33 ASIA PACIFIC: CELL THERAPY TECHNOLOGIES MARKET SNAPSHOT 255
FIGURE 34 REVENUE ANALYSIS OF KEY PLAYERS IN
CELL THERAPY TECHNOLOGIES MARKET, 2021–2023 331
FIGURE 35 MARKET SHARE ANALYSIS OF KEY PLAYERS IN
CELL THERAPY TECHNOLOGIES MARKET, 2023 332
FIGURE 36 CELL THERAPY TECHNOLOGIES MARKET:
COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023 335
FIGURE 37 CELL THERAPY TECHNOLOGIES MARKET: COMPANY FOOTPRINT 336
FIGURE 38 CELL THERAPY TECHNOLOGIES MARKET:
COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023 343
FIGURE 39 EV/EBITDA OF KEY VENDORS 345
FIGURE 40 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF
KEY VENDORS 346
FIGURE 41 CELL THERAPY TECHNOLOGIES MARKET:
BRAND/PRODUCT COMPARATIVE ANALYSIS 346
FIGURE 42 DANAHER CORPORATION: COMPANY SNAPSHOT 351
FIGURE 43 MERCK KGAA: COMPANY SNAPSHOT 360
FIGURE 44 THERMO FISHER SCIENTIFIC INC: COMPANY SNAPSHOT 366
FIGURE 45 LONZA: COMPANY SNAPSHOT 381
FIGURE 46 SARTORIUS AG: COMPANY SNAPSHOT 388
FIGURE 47 AGILENT TECHNOLOGIES: COMPANY SNAPSHOT 395
FIGURE 48 AVANTOR: COMPANY SNAPSHOT 398
FIGURE 49 FRESENIUS: COMPANY SNAPSHOT 406
FIGURE 50 BD: COMPANY SNAPSHOT 409
FIGURE 51 CORNING INCORPORATED: COMPANY SNAPSHOT 413
FIGURE 52 TERUMO CORPORATION: COMPANY SNAPSHOT 418
FIGURE 53 BIO-TECHNE: COMPANY SNAPSHOT 422
FIGURE 54 GENSCRIPT: COMPANY SNAPSHOT 431
FIGURE 55 MAXCYTE: COMPANY SNAPSHOT 436
MarketsandMarkets（マーケッツアンドマーケッツ）は世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。広範な市場を対象にした市場調査レポートを出版しています。
※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間～12時間以内（営業日基準）にご納品可能です。
ライセンス別価格表
調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。
ライセンスタイプ1
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD4,950 | USD6,650 | USD8,150 | USD10,000 |
ライセンスタイプ2
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD7,150 | USD8,500 | USD9,650 | USD11,000 |
ライセンスタイプ3
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD8,150 | お問合せください | お問合せください | お問合せください |
ライセンスタイプ4
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD9,000 | USD10,500 | USD12,000 | USD13,500 |
ミニレポート ※定性調査にフォーカスした調査レポートです。詳細はお問合せください。
| シングルユーザ | コーポレート |
| USD 2,650 | USD 4,250 |
ご購入に関するご案内
価格・納期について
- 価格
- ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
- ライセンス
- シングルユーザライセンス
- 1名のみレポートファイルのご利用が可能です。
- マルチユーザライセンス
- 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
- コーポレートライセンス
- 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
- エンタープライズサイトライセンス
- 特別ライセンスです。適用範囲についてはお問合せください。
- シングルユーザライセンス
- 納品形態
- Eメール
- 納期
- 最短3時間以内にご納品可能です。通常ご注文後24時間以内（営業日基準）
ご注文方法
- レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。
その他
- 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。
株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。
最新調査レポート
- 自動車用アラミド繊維市場規模、シェア、動向、2030年までの世界予測 2025-12-15
- ポリヒドロキシアルカノエート (PHA) 市場規模、シェア、動向、2030年までの世界予測 2025-12-15
- 複合輸送市場規模、シェア、動向、2032年までの世界予測 2025-12-12
- 有機酸市場規模、シェア、動向、2030年までの世界予測 2025-12-11
- ハイブリッドボンディング市場規模、シェア、動向、2032年までの世界予測 2025-12-11